Skip to content

Comparison of ozone rectal insufflation and ozonated autohemotherapy for herpes zoster-associated neuralgia: A prospective, randomized controlled non-inferiority clinical trial

Comparison of ozone rectal insufflation and ozonated autohemotherapy for herpes zoster-associated neuralgia: A prospective, randomized controlled non-inferiority clinical trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092858
Enrollment
Unknown
Registered
2024-11-25
Start date
2024-11-27
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster-associated neuralgia

Interventions

Ozonated autohemotherapy group (O3-AHT group):On the basis of treatment with oral neurotrophic and analgesic drugs, ozonated autohemotherapy was performed for 5 days (concentration was 25 µg/mL)
Ozone rectal insufflation group (O3-RI group):On the basis of treatment with oral neurotrophic and analgesic drugs, ozone rectal insufflation was treated for 5 days (concentration was 30 µg/mL)

Sponsors

Affiliated Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?The age range is 65 to 80. ?The diagnosis was acute herpes zoster pain or postherpetic neuralgia. ?All patients had moderate to severe pain, VAS score =4. ?The analgesic effect of conventional drug treatment is not ideal. ?Can cooperate with treatment and complete follow-up.

Exclusion criteria

Exclusion criteria: Glucose-6-phosphate dehydrogenase deficiency (favism); Toxic diffuse goiter (Graves' disease); Platelet count lower than 50×10^9/L, severe coagulation disorders; Severe unstable cardiovascular diseases, acute myocardial infarction; Acute alcohol intoxication; Massive blood loss, acute hemorrhage, anemia (<90 g/L); Disturbances of water and electrolyte; Seizure, convulsive state; Hemochromatosis, patients undergoing treatment with copper or iron; Hypersensitivity to anticoagulant (sodium citrate); Syncope due to fear of needles or blood; Severe liver insufficiency; Pregnancy; Previous mental disorders or existing cognitive dysfunctions.

Design outcomes

Primary

MeasureTime frame
numerical rating scale for pain before and after treatment;

Secondary

MeasureTime frame
self-rating scale of sleep before and after treatment;Use of analgesic drugs after treatment;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactFang Ming

Affiliated Hospital of Jiangnan University

forlavi@vip.163.com+86 153 0151 6690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026